{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.48","upperLimit":"21.22","value":"8.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"PCyR was defined as the decrease from baseline of 50% or more 8p11 translocated metaphases as seen on classic karyotyping with minimal of 20 metaphases, or FISH.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pemigatinib 13.5 milligrams (mg) was self-administered once daily (QD) as oral tablets on an intermittent dosing (ID) schedule or continuous dosing (CD) schedule. Participants started pemigatinib 13.5 mg on the ID schedule (i.e., 2 weeks on/1 week off) as per the initial Protocol and on the CD schedule in 21-day cycles following a Protocol amendment.","id":"OG000","title":"Pemigatinib 13.5 mg"}],"paramType":"NUMBER","populationDescription":"Full Efficacy-Evaluable Population. Confidence intervals were calculated based on the exact method for binomial distribution.","reportingStatus":"POSTED","timeFrame":"up to 2513 days (120 21-day treatment cycles)","title":"Percentage of Participants Who Achieved a Partial Cytogenetic Response (PCyR) as Assessed by Local Analysis and Investigator Evaluation","type":"SECONDARY","unitOfMeasure":"percentage of participants"}